Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas To Invest ¥5.5 Billion To Construct Chemical Compounds Factory For New Drug Development

This article was originally published in PharmAsia News

Executive Summary

Astellas announced April 7 plans to build a chemical compounds production facility at its Toyama factory. The company plans to invest ¥5.5 billion and start the construction in September. To be completed in 2010, the 9,000 square meter, three-story facility will manufacture multiple compounds to be used in clinical trails for new drug development. Currently, Astellas manufactures atopic drug Protopic (tacrolimus), a chemical compound developed from fermented natural products at the Toyama factory; the company plans to manufacture similar compounds at the new facility. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts